- Home
- PRPH vs SYBX Comparison
PRPH vs SYBX Comparison
Compare PRPH & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- SYBX
- Stock Information
- Founded
- PRPH 1989
- SYBX N/A
- Country
- PRPH United States
- SYBX United States
- Employees
- PRPH N/A
- SYBX N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- PRPH Health Care
- SYBX Health Care
- Exchange
- PRPH Nasdaq
- SYBX Nasdaq
- Market Cap
- PRPH 15.2M
- SYBX 13.9M
- IPO Year
- PRPH 1997
- SYBX N/A
- Fundamental
- Price
- PRPH $0.36
- SYBX $1.71
- Analyst Decision
- PRPH
- SYBX
- Analyst Count
- PRPH 0
- SYBX 0
- Target Price
- PRPH N/A
- SYBX N/A
- AVG Volume (30 Days)
- PRPH 813.9K
- SYBX 53.0K
- Earning Date
- PRPH 08-13-2025
- SYBX 08-07-2025
- Dividend Yield
- PRPH N/A
- SYBX N/A
- EPS Growth
- PRPH N/A
- SYBX N/A
- EPS
- PRPH N/A
- SYBX 0.21
- Revenue
- PRPH $5,845,000.00
- SYBX N/A
- Revenue This Year
- PRPH $221.82
- SYBX N/A
- Revenue Next Year
- PRPH N/A
- SYBX N/A
- P/E Ratio
- PRPH N/A
- SYBX $8.06
- Revenue Growth
- PRPH N/A
- SYBX N/A
- 52 Week Low
- PRPH $0.22
- SYBX $0.90
- 52 Week High
- PRPH $3.37
- SYBX $1.95
- Technical
- Relative Strength Index (RSI)
- PRPH 46.36
- SYBX 82.20
- Support Level
- PRPH $0.35
- SYBX $1.19
- Resistance Level
- PRPH $0.46
- SYBX $1.62
- Average True Range (ATR)
- PRPH 0.03
- SYBX 0.11
- MACD
- PRPH -0.01
- SYBX 0.06
- Stochastic Oscillator
- PRPH 19.36
- SYBX 81.56
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.